EUVIMEDEUVIMED entdecken
Open Access

Enhancing adoptive T cell therapy by disrupting the SKI-SMAD2/3 axis to counteract TGF-β-mediated immunosuppression

Xiaohan Jin, Jingxuan Yu, Xinyu Wu, Qingyong Hu, Xixi Chen, Wenbo Ma, Yude Guan, Dongmei Guo, Yulan Yang, Lingyu Wang, Guofei Jin, Zhenglan Han und 2 weitere

Molecular Therapy · 2026

DOI: 10.1016/j.ymthe.2026.01.028 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy, 2026. Verfasst von Xiaohan Jin und 13 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Basic Medicine, North Sichuan Medical College, Nanchong, Sichuan, China; School of Medical Technology, Tianjin University of Traditional…. Hauptthemen laut MEDLINE: Transforming Growth Factor beta, Smad2 Protein, Smad3 Protein, T-Lymphocytes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Transforming growth factor β (TGF-β) blockade broadly enhances antitumor immunity, while the in vivo mechanisms suppressing T cell-mediated tumor clearance remain elusive. Here, we uncover that TGF-β promotes T cell dysfunction by inducing degradation of the transcriptional co-repressor SKI, abolishing intrinsic repression of TGF-β signaling pathways. Notably, restoring SKI expression in chimeric antigen receptor (CAR)-T cells confers resistance to TGF-β-mediated immunosuppression. Proteomic analyses revealed that TGF-β stimulation triggers interaction between SMAD2/3 and SKI, leading to subsequent proteasomal degradation of SKI. Critically, engineering T cells to express SMAD2/3-binding-deficient SKI mutants (SKImut2/3) disrupts this interaction, preventing SKI degradation and significantly suppressing TGF-β signaling. Repeated tumor antigen stimulation assays under TGF-β pressure demonstrated that CAR-T cells transduced with SKImut2/3 exhibited heightened activation, increased cytokine production, and superior persistent cancer cell killing compared to unmodified cells or SKI-transduced cells in the presence of TGF-β1. Furthermore, transduction of SKImut2/3 in preclinical models of both T cell receptor and CAR-T cell therapies prolonged survival in mice bearing xenografted liquid or solid tumors. Collectively, these findings establish SKImut2/3 expression as a promising therapeutic strategy to enhance both the durability and effector function of T cell-based cancer immunotherapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Transforming Growth Factor betaSmad2 ProteinSmad3 ProteinT-LymphocytesImmunotherapy, AdoptiveDNA-Binding ProteinsProto-Oncogene ProteinsAnimalsHumansMiceSignal TransductionCell Line, TumorImmunosuppression TherapyReceptors, Chimeric AntigenXenograft Model Antitumor Assays

Stichwörter der Autor:innen

SKITGF-β signalingadoptive T cell therapyanti-tumor efficiencyimmunosuppression

Substanzen

Transforming Growth Factor betaSmad2 ProteinSmad3 ProteinDNA-Binding ProteinsProto-Oncogene ProteinsSKI protein, humanReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • Institute of Basic Medicine, North Sichuan Medical College, Nanchong, Sichuan, China; School of Medical Technology, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
  • Institute of Basic Medicine, North Sichuan Medical College, Nanchong, Sichuan, China; Department of Immunology & State Key Laboratory of Common Mechanism Research for Major Diseases, Institute of Basic Medical Sciences,…
  • Institute of Basic Medicine, North Sichuan Medical College, Nanchong, Sichuan, China.
  • School of Psychiatry, North Sichuan Medical College, Nanchong, Sichuan, China.
  • Key Laboratory of Microbial Functional Genomics of the Ministry of Education, College of Life Sciences, Nankai University, Tianjin, China.
  • Institute of Basic Medicine, North Sichuan Medical College, Nanchong, Sichuan, China. Electronic address: nianchaoz@nsmc.edu.cn.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Jin, X., Yu, J., Wu, X., Hu, Q., Chen, X., Ma, W., Guan, Y., Guo, D., Yang, Y., Wang, L., Jin, G., Han, Z., Zhang, S., & Zhang, N. (2026). Enhancing adoptive T cell therapy by disrupting the SKI-SMAD2/3 axis to counteract TGF-β-mediated immunosuppression. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2026.01.028

Vancouver

Jin X, Yu J, Wu X, Hu Q, Chen X, Ma W, et al. Enhancing adoptive T cell therapy by disrupting the SKI-SMAD2/3 axis to counteract TGF-β-mediated immunosuppression. Molecular Therapy. 2026. doi:10.1016/j.ymthe.2026.01.028

BibTeX
@article{Jin2026,
  author = {Jin, Xiaohan and Yu, Jingxuan and Wu, Xinyu and Hu, Qingyong and Chen, Xixi and Ma, Wenbo and Guan, Yude and Guo, Dongmei and Yang, Yulan and Wang, Lingyu and Jin, Guofei and Han, Zhenglan and Zhang, Shumin and Zhang, Nianchao},
  title = {Enhancing adoptive T cell therapy by disrupting the SKI-SMAD2/3 axis to counteract TGF-β-mediated immunosuppression},
  journal = {Molecular Therapy},
  year = {2026},
  doi = {10.1016/j.ymthe.2026.01.028}
}
Kostenlos starten →